<--- Back to Details
First PageDocument Content
Cell biology / Biology / Cell signaling / Cytokines / Signal transduction / Phospholipids / Chemotaxis / Phosphoinositide 3-kinase / Neutrophil / Phosphatidylinositol (3 / 4 / 5)-trisphosphate / Chemokine / Cyclic adenosine monophosphate
Date: 2016-01-18 11:03:32
Cell biology
Biology
Cell signaling
Cytokines
Signal transduction
Phospholipids
Chemotaxis
Phosphoinositide 3-kinase
Neutrophil
Phosphatidylinositol (3
4
5)-trisphosphate
Chemokine
Cyclic adenosine monophosphate

Cell Science at a Glance gradients. It is exhibited by a wide variety of cell types and involves distinct strategies that depend on the environmental conditions. For example, the migration of fibroblasts or keratinocytes

Add to Reading List

Source URL: cellbio7.mcb2225.uconn.edu

Download Document from Source Website

File Size: 410,26 KB

Share Document on Facebook

Similar Documents

Cell Science at a Glance gradients. It is exhibited by a wide variety of cell types and involves distinct strategies that depend on the environmental conditions. For example, the migration of fibroblasts or keratinocytes

Cell Science at a Glance gradients. It is exhibited by a wide variety of cell types and involves distinct strategies that depend on the environmental conditions. For example, the migration of fibroblasts or keratinocytes

DocID: 1ropC - View Document

doi:j.arr

doi:j.arr

DocID: 1qiOh - View Document

Beneficial effects of IH-901 on glucose and lipid metabolisms via activating adenosine monophosphate–activated protein kinase and phosphatidylinositol-3 kinase pathways

Beneficial effects of IH-901 on glucose and lipid metabolisms via activating adenosine monophosphate–activated protein kinase and phosphatidylinositol-3 kinase pathways

DocID: 1mUud - View Document

Chairman’s Note Idelalisib the is first agent to target the phosphatidylinositol-3-kinase (PI3K) pathway and the second oral agent approved by the FDA, in July 2014, for treatment of relapsed/refractory chronic lymphoc

Chairman’s Note Idelalisib the is first agent to target the phosphatidylinositol-3-kinase (PI3K) pathway and the second oral agent approved by the FDA, in July 2014, for treatment of relapsed/refractory chronic lymphoc

DocID: 1m4mv - View Document

Research Article  PIK3CA Cooperates with Other Phosphatidylinositol 3¶-Kinase Pathway Mutations to Effect Oncogenic Transformation 1,3

Research Article PIK3CA Cooperates with Other Phosphatidylinositol 3¶-Kinase Pathway Mutations to Effect Oncogenic Transformation 1,3

DocID: 1kNe5 - View Document